Shaily Engineering Plastics Ltd Q4 FY26 Earnings Call: Secures Rs. 4,423 Crore Pen Injector Order, EBITDA Margin Expands 630 bps

Shaily Engineering Plastics Ltd held its Q4 FY26 earnings call on May 19, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Record Profitability in a Transition Year

• FY26 consolidated revenue: Rs.991 crores— up 26% YoY, with healthcare surging 139% to Rs.393 crores (40% of total vs 21% in FY25).
• FY26 EBITDA: Rs.288 crores (29% margin)— up 61% YoY, with margins expanding 630 bps YoY; PAT at Rs.170 crores (17.2% margin), up 83% YoY.
• Q4 FY26 revenue: Rs.237 crores— up 9% YoY, with healthcare at Rs.113 crores (+110% YoY) partially offset by consumer at Rs.102 crores (-31% YoY).
• Q4 EBITDA: Rs.69 crores (29.3% margin)— up 27% YoY, with margins expanding 420 bps YoY; PAT at Rs.40 crores (17% margin), up 40% YoY.
• Cash PAT for FY26: Rs.219 crores— up 62% YoY, reflecting strong cash generation alongside earnings growth.
• ROCE of 35.8%, ROE of 26.9%— with debt-to-equity at 0.3x and fixed asset turnover at 1.7x as of March 31, 2026.
• Consumer segment declined 9% to Rs.512 crores in FY26— driven by weakening US/Europe home furnishing demand and Q4 Middle East order cancellations due to the war.

Semaglutide Pens Drive Healthcare Transformation

• Healthcare revenue surged 139% to Rs.393 crores in FY26— becoming 40% of consolidated revenue (up from 21% in FY25), driven by commercial semaglutide pen supplies.
• Commercial pen injector supplies commenced in Q4 FY26— for both India and Canadian markets, with a customer receiving tentative US approval.
• Rs.4,423 crore pen injector order from a large domestic pharma company— spread over four years; customer name withheld under NDA.
• CRV pen volumes: 23.5 million units in FY26— below the guided 25.6–26 million due to capacity constraints; management guided ~36 million for FY27 and ~50 million for FY28.
• Canada launches saw positive early feedback— only two complaints received (user error and printing issue); management stated ~70% of top six Canadian filers use Shaily's device.
• No commercial agreements with innovator GLP-1 companies as of May 2026— management confirmed no signed agreements or commercial engagements with innovative GLP-1 segment players.
• Brazil launch expected by end of May/June 2026 (Q1 FY27)— with Turkey and Mexico launches to follow; no specific timeline provided for the latter.

Semiconductor & Consumer Electronics Open New Avenues

• Shaily is the sole Indian manufacturing partner for a Korean semiconductor customer— supplying conductive plastic trays to OSAT players in India, with commercial supplies expected from Q4 FY26-27.
• FY27 chip tray supply target: 36 million units— corrected from an earlier mention of 40–42 million; management views this as a volume-driven consumable business.
• Consumer electronics component supplies commenced in Q4 FY26— with shipments in India and for export; management reiterated a multi-year opportunity over 5 years.
• Consumer electronics EBITDA margins to remain single-digit— until scale reaches ~$15–20 million, as overheads stay high initially due to technical complexity (Amit Sanghvi, MD).
• Global competitors exist in Korea, China, and the Philippines— but management noted chip manufacturers would likely avoid daily imports over a longer horizon, supporting local production.
• Eye applicator machines commissioned for a single customer— replacing an imported item for regulated markets; commercialization planned for FY26-27.

Pen Injector Capacity Triples; Efficiency Improving

• Pen injector capacity to reach 80 million units— 30M existing + 25M added in March (Q4 FY26) + 25M planned by July–August (Q2 FY27).
• New 25M semaglutide line running at ~45% OEE— at 34–35 ppm on an 80 ppm line; management targets 65–67 ppm by end of FY27 for both new lines.
• Rejection rate reduced to 8%— down from ~30% in Q3 FY26;breakdown issues need permanent resolution.
• Machine utilization improved to 47.6% in FY26— up from 42.2% in FY25, reflecting better capacity deployment.
• Investment cycle for new lines extended to 18–24 months— from trigger to on-stream (previously ~12 months); future capacity additions should see lower initial rejection rates.
• Target combined optimal capacity of 40–42 million pens for FY27— from the two new lines; management targets 35–40 million pens from new capacity by end of FY28 (March 2028).
• Abu Dhabi greenfield capex progressing— geopolitical tensions seen as short-term with buffer factored in; benefits include lower operational costs, supply chain ease, and international talent access.

Sustainable Margins Above 28%; Consumer Drag Easing

• Sustainable EBITDA margin of ~28%+ confirmed— management stated the current ~28%+ margin is sustainable even after Abu Dhabi capacity expansion, with expected year-on-year improvement.
• Healthcare segment now 40% of revenue— up from 21% in FY25, shifting the mix toward higher-margin pen injector products.
• Consumer segment declined to 52% of revenue— down from 71% in FY25, with degrowth accelerating in H2 FY26 due to US/Europe demand weakness and Q4 Middle East order cancellations.
• UK subsidiary margins were lowest in Q3 and Q4 FY26— attributed to longer-term milestone-based projects and a shift toward next-gen drug delivery devices; management advised looking at combined UK+UAE margins.
• Industrial segment grew 41% to Rs.87 crores in FY26— providing a small but growing diversification benefit.
• Consumer recovery depends on global situation improving— management declined to specify when consumer demand might rebound or provide a quarterly revenue breakdown.

FY27 Priorities: Scale, Build, Deepen, Restore

• FY27 pen injector volume guidance: ~36 million units— with capacity ramp-up risk flagged for new lines arriving in August FY27; FY28 target at ~50 million units.
• Board approved enabling resolution to raise up to Rs.500 crores for FY26-27— for time-sensitive, capital-intensive opportunities requiring 50–100 million devices/year capacity (e.g., auto-injectors), with supplies from Q4 FY26-27.
• FY27 priorities: scale healthcare, build Abu Dhabi facility, deepen consumer electronics & semiconductor programs, restore consumer growth— as stated by management.
• Overall pen production target of 40–60 million units in 24–30 months— (approximately FY28–FY29), reflecting the multi-year ramp trajectory.
• Management expressed confidence in sustainable growth years ahead— citing FY26 execution and continued operational improvement as foundation.
• Management declined to provide quarterly revenue breakdown or specific consumer rebound timeline— maintaining a conservative disclosure stance on near-term visibility.